Certain molecular subtypes of cancer, both solid tumors as well as diffuse ones, were reported to be vulnerable to statins, FDA-approved cholesterol-lowering drugs, potent inhibitors of the rate-limiting enzyme of the mevalonate pathway, HMGCR (11). Here, HMGCR is linked to cancer.